Amino Acid Metabolism, Inborn Errors Clinical Trial
Official title:
Therapeutic and Metabolic Studies of Urea Cycle Disorders: Part A: Nitrogen Flux and Ureagenesis; Part B (Closed): Phase I Adenovirus Vector-Mediated Gene Therapy for Ornithine Transcarbamylase Deficiency
RATIONALE: The urea cycle is the process in which nitrogen is removed from the blood and
converted into urea, a waste product found in urine . Urea cycle disorders are inherited
disorders caused by the lack of an enzyme that removes ammonia from the bloodstream. Gene
therapy is treatment given to change a gene so that it functions normally. Studying the
treatment and metabolism of patients with urea cycle disorders may be helpful in developing
new treatments for these disorders.
PURPOSE: Two-part clinical trial to study the treatment and metabolism of patients who have
urea cycle disorders.
PROTOCOL OUTLINE: This protocol involves 2 clinical studies. Part A is a metabolic study of
glutamine conversion to urea at different levels of protein intake, while on and off
medications. Part B is a dose escalation study of a first-generation adenoviral vector with
an E1 deletion and an E3 deletion substitution (d1309) expressing ornithine transcarbamylase
(OTC).
In Part A, diet is controlled for protein and calories. Intravenous glutamine and urea are
administered. Controls are given intravenous arginine, phenylacetate, and benzoate.
In Part B, groups of 3 patients are given a single low, intermediate, or high dose of
intravenous OTC vector. Allopurinol is administered every 12 hours for 12 days. As of
12/10/1999, Part B of the study is closed.
;
Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06337864 -
Evaluating the Efficacy and Safety of Large Neutral Amino Acids in the Treatment of Classical Phenylketonuria
|
N/A | |
Terminated |
NCT01141075 -
Ataluren for Nonsense Mutation Methylmalonic Acidemia
|
Phase 2 | |
Completed |
NCT00004767 -
Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders
|
Phase 2 | |
Completed |
NCT00345605 -
Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder
|
Phase 2 | |
Recruiting |
NCT00237315 -
Longitudinal Study of Urea Cycle Disorders
|